Dividend affirmation and earnings catalyst put Abbott Laboratories stock in focus

Recent commentary on Abbott Laboratories (ABT) has centered on upcoming earnings and Citi highlighting the value of its diversified healthcare businesses, setting the stage for closer attention to the stock.

The reaffirmed quarterly dividend and the approaching July 16 earnings report give investors timely reference points as they weigh Abbott Laboratories stock, its current business mix, and expectations around key product platforms.

At a share price of $88.41, Abbott Laboratories has seen its 90 day share price return fall 16.17% and its 1 year total shareholder return decline 32.16%, even as investors weigh the long running dividend track record, upcoming earnings update, and references to Abbott in growth areas such as ECG monitoring and longevity focused healthcare.

If Abbott’s earnings and product news have you reassessing your watchlist, it may be a suitable time to consider other healthcare names linked to AI driven tools and 40 healthcare AI stocks

With Abbott Laboratories stock down over the past year and trading below some analyst estimates of underlying business value, the key question is whether today’s price reflects a discount or whether markets already see future growth coming.

Most Popular Narrative: 24.1% Undervalued

Against Abbott Laboratories’ last close at $88.41, the most followed narrative points to a fair value of $116.54. This frames a sizeable valuation gap that hinges on long term earnings power and cash flow resilience.

Analysts expect earnings to reach $9.5 billion (and earnings per share of $5.45) by about June 2029, up from $6.3 billion today. However, there is a considerable amount of disagreement amongst the analysts with the most bullish expecting $11.3 billion in earnings, and the most bearish expecting $7.2 billion.

Curious what sits behind that earnings ramp, the margin shift and the premium P/E the narrative is willing to pay for Abbott Laboratories in 2029? The model leans heavily on steady top line compounding, improving profitability and a discount rate just under 8% to bridge from today’s price to that fair value. The detailed assumptions may surprise you.

Result: Fair Value of $116.54 (UNDERVALUED)

However, sustained pricing pressure in diagnostics, along with any prolonged impact from tariffs or currency swings, could challenge Abbott Laboratories earnings path and the current valuation narrative.

Another View: What Abbott Laboratories’ P/E Says About Value Risk

The SWS DCF model points to Abbott Laboratories trading at a discount, yet the current P/E of 24.6x is slightly above the US Medical Equipment industry at 24.4x and below an estimated fair ratio of 30.1x. That mix of modest premium and fair ratio headroom raises a simple question: how much re rating room do you really think is left in this stock?

Next Steps

If this mix of concern and optimism around Abbott Laboratories has you undecided, take time to review the details and weigh the trade offs yourself with 4 key rewards and 2 important warning signs

Looking for more investment ideas beyond Abbott Laboratories?

If Abbott Laboratories has sharpened your focus, do not stop there. Use the Simply Wall St screener to surface fresh opportunities that might better fit your goals.

• Spot potential bargains early by scanning companies that combine quality fundamentals with room for a re rating using the 45 high quality undervalued stocks.
• Strengthen your income stream by assessing companies that aim to support higher yields through the 8 dividend fortresses.
• Prioritize resilience by focusing on companies that pair financial stability with solid fundamentals via the solid balance sheet and fundamentals stocks screener (48 results).

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.